Alnylam Pharmaceuticals has developed an RNA interference treatment, zilebesiran, which has shown to reduce blood pressure for six months with one to two doses in a mid-stage clinical trial.
A systolic blood pressure treatment target under 120 mm Hg improves outcomes and saves lives compared with a threshold of 140 mm Hg for higher risk patients with hypertension.
Chronic insufficient sleep can increase insulin resistance in healthy women, particularly postmenopausal women.
Reducing sodium intake can help lower blood pressure as effectively as medication.
Recent studies have shed light on various aspects of blood pressure management and its impact on health. One such study conducted by the National Institutes of Health (NIH) found that chronic insufficient sleep can increase insulin resistance in healthy women, particularly postmenopausal women. This finding underscores the importance of adequate sleep in maintaining overall health.
In another development, Alnylam Pharmaceuticals has developed an RNA interference treatment, zilebesiran, which has shown to reduce blood pressure for six months with one to two doses in a mid-stage clinical trial. The company aims to develop this treatment as an add-on or alternative to current daily blood pressure medications, potentially offering a new approach to managing this common health condition.
Dietary habits also play a significant role in blood pressure management. A study suggests that reducing sodium intake can help lower blood pressure as effectively as medication. The low sodium diet led to significant reductions in blood pressure, regardless of whether participants were on blood pressure medication, highlighting the importance of dietary choices in health outcomes.
Finally, the ESPRIT trial from China affirms that a systolic blood pressure treatment target under 120 mm Hg improves outcomes and saves lives compared with a threshold of 140 mm Hg for higher risk patients with hypertension. Cardiovascular deaths also fell by 39%, and death from any cause by 21% with the lower target. This study reinforces the importance of maintaining optimal blood pressure levels for cardiovascular health.
Alnylam Pharmaceuticals has developed an RNA interference treatment, zilebesiran, which has shown to reduce blood pressure for six months with one to two doses in a mid-stage clinical trial.
The company aims to develop this treatment as an add-on or alternative to current daily blood pressure medications.
The ESPRIT trial from China affirms that a systolic blood pressure treatment target under 120 mm Hg improves outcomes and saves lives compared with a threshold of 140 mm Hg for higher risk patients with hypertension.
Cardiovascular deaths also fell by 39%, and death from any cause by 21% with the lower target.
Accuracy
No Contradictions at Time
Of
Publication
Deception
(100%)
None Found At Time Of
Publication
Fallacies
(100%)
None Found At Time Of
Publication
Bias
(100%)
None Found At Time Of
Publication
Site
Conflicts
Of
Interest (100%)
None Found At Time Of
Publication
Author
Conflicts
Of
Interest (80%)
Li disclosed funding via Fuwai Hospital from China's Ministry of Science and Technology for the trial and from Servier (Tianjin) Pharmaceutical, Lilly, and BioValley.
One study found that chronic insufficient sleep can increase insulin resistance in healthy women, particularly postmenopausal women.
Another study suggested that improved techniques for rescue breathing during CPR could save more lives.
A third study found that the type of transfusion approach used for adults who developed anemia after a heart attack did not significantly affect their likelihood of having another heart attack or dying within 30 days.